Have Been Scheduled
BDX - Upcoming Dividend Payouts
Next Ex-Dividend Date
|Amount||Declare Date||Ex-Dividend Date ▲||Record Date||Pay Date||Payout Type|
|No Upcoming Dividend Dates|
BDX - Dividend Yield & Stock Price History
Current Dividend Yield
BDX - Dividend Payout History
Current Annual Payout
Dividend.com DARS Rating™ Breakdown for BDX
BDX - Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal Dividend Growth History for BDX.||10.1%||10.0%||42 years|
BDX - Historical Annual Dividend Data & Growth
Payouts Increasing For
|Payout Amount||Calendar Year||Annual Growth|
BDX - Historical Dividend Data
Payouts Increasing For
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
Becton Dickinson (BDX) - News
Over the last month, the S&P 500 Index has shed upwards of 7%; prior to this sell-off, the S&P 500 was up just over 8% for the year. Put...
Tuesday's Analyst Moves: Time Warner Inc, Intercontinental Exchange Inc, Las Vegas Sands Corp., More (TWX, ICE, LVS, More)Oct 7, 2014Before Tuesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Monday's Analyst Moves: Oracle Corporation, Enterprise Products Partners L.P., Colgate-Palmolive Company, More (ORCL, EPD, CL, More)Oct 6, 2014Before Monday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
On Sunday it was announced that medical technology company Becton Dickinson (BDX) will be acquiring CareFusion (CFN) for $58 per share in a stock...
Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Tuesday Analyst Moves: Johnson & Johnson, Yum! Brands, Inc., Target Corporation, More (JNJ, YUM, TGT, More)Jan 7, 2014Before Tuesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Becton, Dickinson and Co. Earnings Decline; Beats Estimates; Revenue Rises (BDX)Aug 1, 2013On Thursday, medical technology company Becton, Dickinson and Co. (BDX) released its third quarter earnings results, which were hurt by higher costs and increased taxes. Despite the rise in expenses, the company still beat analysts' earnings estimates by 10 cents per share. The Franklin Lakes, NJ-based company reported third quarter earnings of $301.55 million, or $1.52 per share, down from $326.87 million, or $1.59 per share. Excluding special items, earnings were $1.58 per share, beating analysts' estimate of $1.48 per share. Revenue for the quarter was $2.05 billion, up from $1.98 billion a year ago. On average, analysts expected to see revenue of $2.05 billion. Looking ahead to FY2013, earnings are expected to be between $5.65 and $5.68 per share. Adjusted earnings are expected to be between $5.72 and $5.75 per share. Analysts are estimating full year earnings of $5.74 per share. Becton, Dickinson and Co shares were mostly flat during pre-market trading Thursday. The stock is up 33% YTD. The Bottom Line Shares of Becton, Dickinson and Co. (BDX) have a 1.91% yield based on Wednesday's closing price of $103.72. Becton, Dickinson and Co. (BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
ISI Group Starts Coverage on Becton, Dickinson and Co. (BDX)Jun 25, 2013ISI Group reported on Tuesday that it has begun coverage on medical technology company, Becton, Dickinson and Co. (BDX) . The firm has begun coverage on BDX with a "Buy" rating and $106.50 price target. This price target suggests an 8% increase from the stock's current price of $97.83. An analyst from the firm commented, “we view Becton, Dickinson and Co (BDX) as a premier provider of medical devices, diagnostic instruments, and reagents to hospitals as well as pharma, academic, and clinical labs. We contend that the company's attractively diversified portfolio (Medical ~50% of revs, Diagnostics ~35% of revs and Biosciences ~15% of revs), should allow for mid single digit top-line growth over the medium-term. This will be driven mainly by new product momentum, increased leverage to the emerging markets, and continued strength in safety engineered products. With respect to new product momentum, we see several offerings that have been underappreciated by the Street including: BD Max (MDx), BD Rx (prefilled generics), Kiestra microbiology automation (MDx), Carmel closed drug transfer systems, Accuri flocytometry, and Sirigen (reagents). When combined with advancements in pen needles, we expect innovation to contribute ~250 bps to organic growth going forward. Lastly, we believe that emerging markets (~25% of revs) will continue to grow low double digits (with China up strong double digits), while safety engineered products (prevention of needle sticks) should expand in the high single digit range.” Becton, Dickinson shares were mostly flat during Tuesday morning trading. The stock is up 25% YTD. The Bottom Line Shares of Becton, Dickinson and Co. (BDX) have a 2.02% yield, based on Tuesday morning's price of $97.83. Becton, Dickinson and Co. (BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Early Flu Season Helps Boost Sales for Becton, Dickinson and Co. (BDX)Feb 5, 2013Global medical technology company, Becton, Dickinson and Co. (BDX) reported increased profits on Tuesday due to an early flu season. The Franklin Lakes, NJ based company reported first quarter earnings of $625.44 million, or $3.13 per share, up from $262.99 million, or $1.21 per share last year. Earnings from continuing operations came in at $1.35 per share, up from $1.14 last year, and beating analysts estimate of $1.24 per share. Revenue for the quarter came in at $1.9 billion, up 3.7% from last year, beating analysts estimate of $1.86 billion. Sales in the United States rose by 3%. International sales saw a 4.3% upside. The company reported that the early flu season had a significant impact on earnings for the quarter. Looking forward, the company expects to see FY2013 earnings in the range of $5.69 to $5.72 per share. BDX also sees sales growth of 4% to 4.5% for the year. Analysts are expecting to see earnings of $5.65 per share with $7.94 billion in revenue. Becton, Dickinson, & Co. shares were up $1.94, or 2.28% during premarket trading Tuesday. The stock has increased 6.5% in the past year. The Bottom Line Shares of BDX have a 2.33% dividend yield, based on Monday's closing price of $85.16 and the company's annualized dividend payout of $1.98 per share. Becton, Dickinson and Co.(BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts Becton Dickinson (BDX) has...